XENTION and SERVIER pharma partners by entering into a multi-year agreement for the development and commercialisation of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of atrial fibrillation .
Under the terms of the agreement, Servier has received an option to acquire certain intellectual property rights and to further develop and commercialise XEN-D0103 in all territories except the USA and Japan.
All rights in the USA and Japan will be retained by Xention.
During the option period, the pharma partnerswill undertake a joint programme of clinical development of XEN-D0103 undertaking two phase 2 clinical studies aimed at demonstrating the efficacy of XEN-D0103 in reducing AF burden in paroxysmal AF.
In addition to an upfront fee, Servier will pay an option fee as well as a series of milestones totalling €120 million.
When Servier exercises its option, it will be responsible for the further clinical development and commercialisation of XEN-D0103 within its territories.
XEN-D0103 is a potent and selective blocker of Kv1.5, a potassium channel expressed in the atria, which represents an exciting new target for atrial fibrillation.
For further deal information visit Current Agreements (subscription required)
Read: more on Servier company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Servier
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity